Mepolizumab in Hypereosinophilic Syndrome: A Systematic Review and Meta-analysis
We aimed to evaluate the efficacy and safety of mepolizumab (MEP) in the management of hypereosinophilic syndrome (HES). A systematic search was performed, and articles published until March 2021 were analyzed. The primary efficacy results evaluated were hospitalization rate related to HES, morbidit...
Main Authors: | José Mario Alves Júnior, Francisco Eduardo Prota, Danilo Villagelin, Fernanda Bley, Wanderley Marques Bernardo |
---|---|
Format: | Article |
Language: | English |
Published: |
Elsevier España
2021-10-01
|
Series: | Clinics |
Subjects: | |
Online Access: | http://www.scielo.br/scielo.php?script=sci_arttext&pid=S1807-59322021000100427&tlng=en |
Similar Items
-
Characterization of disease flares and impact of mepolizumab in patients with hypereosinophilic syndrome
by: Fabrizio Pane, et al.
Published: (2022-08-01) -
Association Between Baseline Therapy and Flare Reduction in Mepolizumab-Treated Patients With Hypereosinophilic Syndrome
by: Andreas Reiter, et al.
Published: (2022-04-01) -
Idiopathic hypereosinophilic syndrome with eosinophilic cellulitis-like cutaneous involvement treated with mepolizumab and dapsone
by: Madeleine Lachance, MD, et al.
Published: (2022-04-01) -
Mepolizumab therapy improves the most bothersome symptoms in patients with hypereosinophilic syndrome
by: Florence Roufosse, et al.
Published: (2023-03-01) -
Low-dose anti-IL 5 treatment in idiopathic hypereosinophilic syndrome: towards a precision medicine approach for remission maintenance
by: Marco Caminati, et al.
Published: (2023-09-01)